Date: 2015-05-12
Type of information: Series B financing round
Company: Juventas Therapeutics (USA - OH)
Investors: Green Cross Holdings (South Korea) POSCO Capital (South Korea) other new and existing investors
Amount: $13.5 million
Funding type:
Planned used:
Others: * On May 12, 2015, Juventas Therapeutics, Inc., a clinical-stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases, announced that the company has secured $13.5 million in financing. Green Cross Holdings and POSCO Capital led a $7.5 million Series B-2 equity investment that included participation from other new and existing investors. Additionally, Juventas secured $6 million in debt financing from Oxford Finance LLC, with an opportunity to obtain an additional $9 million if specific milestones are met.
Therapeutic area: Cardiovascular diseases
